NCT00027872View on ClinicalTrials.gov

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

July 31, 2007

Study Completion Date

January 31, 2009

Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Cellular Diagnosis, Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

tipifarnib

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

21287-8936

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00027872 - Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter